BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ezharmia (valemetostat tosylate) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ezharmia (valemetostat tosylate)\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04388852-2791@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ezharmia (valemetostat tosylate): Phase 1 readout est. (NCT04388852
 )
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 1.\nStudy: DS3201 and 
 Ipilimumab for the Treatment of Metastatic Prostate\, Urothelial and Renal
  Cell Cancers\nEstimated primary completion: 31 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04388852
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807632-2791@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ezharmia (valemetostat tosylate): Phase 1 readout est. (NCT06807632
 )
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 1.\nStudy: A Study of 
 Valemetostat in Combination With Atezolizumab in People With Lung Cancer\n
 Estimated primary completion: January 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06807632
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03930953-2791@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Ezharmia (valemetostat tosylate): Phase 1/2 readout est. (NCT039309
 53)
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 1/2.\nStudy: A Safety 
 and Preliminary Efficacy Study of CC-99282\, Alone and in Combination With
  Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodg
 kin Lymphomas (R/R NHL)\nEstimated primary completion: 7 April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/valemetostat-tosylate#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03930953
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05683171-2791@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ezharmia (valemetostat tosylate): Phase 1/2 readout est. (NCT056831
 71)
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 1/2.\nStudy: A Phase 1
 /2\, Open-label Study of Valemetostat in Combination With Rituximab and Le
 nalidomide in Relapsed or Refractory Follicular Lymphoma\nEstimated primar
 y completion: 30 September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/valemetostat-tosylate#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05683171
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06294548-2791@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Ezharmia (valemetostat tosylate): Phase 1/2 readout est. (NCT062945
 48)
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 1/2.\nStudy: A Study o
 f Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HC
 C\nEstimated primary completion: 30 January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06294548
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244341-2791@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ezharmia (valemetostat tosylate): Phase 1 readout est. (NCT07244341
 )
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 1.\nStudy: A Study of 
 Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Cas
 tration Resistant Prostate Cancer (mCRPC)\nEstimated primary completion: 3
 1 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/valem
 etostat-tosylate#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07244341
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644768-2791@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Ezharmia (valemetostat tosylate): Phase 1/2 readout est. (NCT066447
 68)
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 1/2\, Non-Small Cell L
 ung Cancer.\nStudy: A Study of Valemetostat Tosylate Plus Pembrolizumab Ve
 rsus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Al
 terations\nEstimated primary completion: 30 March 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06644768
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06244485-2791@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Ezharmia (valemetostat tosylate): Phase 1 readout est. (NCT06244485
 )
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 1.\nStudy: A Study of 
 Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid 
 Tumors\nEstimated primary completion: 1 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06244485
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632977-2791@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20300411
DTEND;VALUE=DATE:20300412
SUMMARY:Ezharmia (valemetostat tosylate): Phase 2 readout est. (NCT06632977
 )
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 2.\nStudy: Targeted Tr
 eatment for Metastatic Prostate Cancer\, The PREDICT Trial\nEstimated prim
 ary completion: 11 April 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/valemetostat-tosylate#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06632977
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633979-2791@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Ezharmia (valemetostat tosylate): Phase 1 readout est. (NCT05633979
 )
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 1.\nStudy: Phase 1b St
 udy of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Derux
 tecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer\nE
 stimated primary completion: 31 December 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05633979
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07303387-2791@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Ezharmia (valemetostat tosylate): Phase 2 readout est. (NCT07303387
 )
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 2.\nStudy: Efficacy an
 d Safety of the Valemetostat in Patients With Selected Solid Tumors.\nEsti
 mated primary completion: 28 February 2031. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07303387
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
